Skip to main content
PMC home page
Philosophical Transactions of the Royal Society B: Biological Sciences logoLink to Philosophical Transactions of the Royal Society B: Biological Sciences
. 2003 May 29;358(1433):961–966. doi: 10.1098/rstb.2003.1272

Gaucher disease and the clinical experience with substrate reduction therapy.

Ari Zimran 1, Deborah Elstein 1
PMCID: PMC1693183  PMID: 12803930

Abstract

Gaucher disease is caused by an enzymatic defect with consequent accumulation of glucocerebroside. Type I, the non-neuronopathic form, is rather common and panethnic. Patients may present with hepatosplenomegaly, anaemia, thrombocytopenia and skeletal or lung involvement. Enzyme replacement therapy ameliorates disease symptoms and signs; however, it involves lifelong intravenous therapy, is costly and is incapable of crossing the blood-brain barrier. Substrate reduction with N-butyldeoxynojirimycin (OGT 918) is a harbinger of oral iminosugars for glycolipid storage disorders. Long-term data in the seminal trial (100 mg three times per day), demonstrate safety and efficacy in adult type I patients naive to enzyme therapy, and suggest its application in patients unwilling or unable to receive enzyme replacement and tolerating side effects, including diarrhoea, weight loss, tremor and peripheral neuropathy (mostly reversible with dose reduction or withdrawal). Dose dependency was demonstrated with 50 mg three times per day. In patients stabilized on enzyme therapy switched from or in combination with enzyme, no deterioration in disease parameters was seen but side effects were as above. Although efficacy is less dramatic than enzyme treatment, it may be that plateaux are achieved asymptotically so therapeutic outcomes with OGT 918 may ultimately be comparable. Yet, given the above side effects and the lack of long-term experience, patients with very mild manifestations would probably not be appropriate candidates.

Full Text

The Full Text of this article is available as a PDF (147.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe A., Wild S. R., Lee W. L., Shayman J. A. Agents for the treatment of glycosphingolipid storage disorders. Curr Drug Metab. 2001 Sep;2(3):331–338. doi: 10.2174/1389200013338414. [DOI] [PubMed] [Google Scholar]
  2. Aerts Johannes M., Hollak Carla, Boot Rolf, Groener Ans. Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):905–914. doi: 10.1098/rstb.2003.1273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barton N. W., Brady R. O., Dambrosia J. M., Di Bisceglie A. M., Doppelt S. H., Hill S. C., Mankin H. J., Murray G. J., Parker R. I., Argoff C. E. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med. 1991 May 23;324(21):1464–1470. doi: 10.1056/NEJM199105233242104. [DOI] [PubMed] [Google Scholar]
  4. Brady Roscoe O. Enzyme replacement therapy: conception, chaos and culmination. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):915–919. doi: 10.1098/rstb.2003.1269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Butters Terry D., Mellor Howard R., Narita Keishi, Dwek Raymond A., Platt Frances M. Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):927–945. doi: 10.1098/rstb.2003.1278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cox T., Lachmann R., Hollak C., Aerts J., van Weely S., Hrebícek M., Platt F., Butters T., Dwek R., Moyses C. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 2000 Apr 29;355(9214):1481–1485. doi: 10.1016/S0140-6736(00)02161-9. [DOI] [PubMed] [Google Scholar]
  7. Dawson A., Elias D. J., Rubenson D., Bartz S. H., Garver P. R., Kay A. C., Bloor C. M., Beutler E. Pulmonary hypertension developing after alglucerase therapy in two patients with type 1 Gaucher disease complicated by the hepatopulmonary syndrome. Ann Intern Med. 1996 Dec 1;125(11):901–904. doi: 10.7326/0003-4819-125-11-199612010-00005. [DOI] [PubMed] [Google Scholar]
  8. Dweck Altoon, Abrahamov Ayala, Hadas-Halpern Irith, Bdolach-Avram Tali, Zimran Ari, Elstein Deborah. Type I Gaucher disease in children with and without enzyme therapy. Pediatr Hematol Oncol. 2002 Sep;19(6):389–397. doi: 10.1080/08880010290097143. [DOI] [PubMed] [Google Scholar]
  9. Elstein D., Abrahamov A., Hadas-Halpern I., Zimran A. Withdrawal of enzyme replacement therapy in Gaucher's disease. Br J Haematol. 2000 Aug;110(2):488–492. doi: 10.1046/j.1365-2141.2000.02177.x. [DOI] [PubMed] [Google Scholar]
  10. Elstein D., Klutstein M. W., Lahad A., Abrahamov A., Hadas-Halpern I., Zimran A. Echocardiographic assessment of pulmonary hypertension in Gaucher's disease. Lancet. 1998 May 23;351(9115):1544–1546. doi: 10.1016/S0140-6736(98)10194-0. [DOI] [PubMed] [Google Scholar]
  11. Goitein O., Elstein D., Abrahamov A., Hadas-Halpern I., Melzer E., Kerem E., Zimran A. Lung involvement and enzyme replacement therapy in Gaucher's disease. QJM. 2001 Aug;94(8):407–415. doi: 10.1093/qjmed/94.8.407. [DOI] [PubMed] [Google Scholar]
  12. Grabowski G. A., Horowitz M. Gaucher's disease: molecular, genetic and enzymological aspects. Baillieres Clin Haematol. 1997 Dec;10(4):635–656. doi: 10.1016/s0950-3536(97)80032-7. [DOI] [PubMed] [Google Scholar]
  13. Grabowski G. A., Leslie N., Wenstrup R. Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev. 1998 Jun;12(2):115–133. doi: 10.1016/s0268-960x(98)90023-6. [DOI] [PubMed] [Google Scholar]
  14. Harats D., Pauzner R., Elstein D., Many A., Klutstein M. W., Kramer M. R., Farfel Z., Zimran A. Pulmonary hypertension in two patients with type I Gaucher disease while on alglucerase therapy. Acta Haematol. 1997;98(1):47–50. doi: 10.1159/000203562. [DOI] [PubMed] [Google Scholar]
  15. Heitner Rene, Elstein Deborah, Aerts Johannes, Weely Sonja van, Zimran Ari. Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis. 2002 Mar-Apr;28(2):127–133. doi: 10.1006/bcmd.2002.0497. [DOI] [PubMed] [Google Scholar]
  16. Moyses Chris. Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):955–960. doi: 10.1098/rstb.2003.1271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Platt F. M., Neises G. R., Dwek R. A., Butters T. D. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem. 1994 Mar 18;269(11):8362–8365. [PubMed] [Google Scholar]
  18. Platt F. M., Neises G. R., Reinkensmeier G., Townsend M. J., Perry V. H., Proia R. L., Winchester B., Dwek R. A., Butters T. D. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science. 1997 Apr 18;276(5311):428–431. doi: 10.1126/science.276.5311.428. [DOI] [PubMed] [Google Scholar]
  19. Platt Frances M., Jeyakumar Mylvaganam, Andersson Ulrika, Heare Tanya, Dwek Raymond A., Butters Terry D. Substrate reduction therapy in mouse models of the glycosphingolipidoses. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):947–954. doi: 10.1098/rstb.2003.1279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Radin N. S. Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj J. 1996 Apr;13(2):153–157. doi: 10.1007/BF00731489. [DOI] [PubMed] [Google Scholar]
  21. Tierney M., Pottage J., Kessler H., Fischl M., Richman D., Merigan T., Powderly W., Smith S., Karim A., Sherman J. The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 15;10(5):549–553. [PubMed] [Google Scholar]
  22. Weinreb Neal J., Charrow Joel, Andersson Hans C., Kaplan Paige, Kolodny Edwin H., Mistry Pramod, Pastores Gregory, Rosenbloom Barry E., Scott C. Ronald, Wappner Rebecca S. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med. 2002 Aug 1;113(2):112–119. doi: 10.1016/s0002-9343(02)01150-6. [DOI] [PubMed] [Google Scholar]

Articles from Philosophical Transactions of the Royal Society B: Biological Sciences are provided here courtesy of The Royal Society

RESOURCES